1887

Abstract

SUMMARY

Using a guinea-pig model of genital herpes simplex virus (HSV) infection we explored the protection afforded by preinfection immunization with HSV glycoproteins. Glycoprotein immunogens prepared by recombinant DNA technology were found to be as effective as immunogens purified from HSV-infected cell cultures. Immunized animals developed less severe primary disease and also experienced less frequent recurrent infections. Protection was influenced by both adjuvant and route of administration. These studies suggest that recombinant HSV glycoproteins may be effective immunogens for human clinical trials, but that the development of an effective vaccine will require identification of new potent adjuvants that are safe for human use.

Keyword(s): guinea-pig , HSV and vaccines
Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-70-12-3177
1989-12-01
2022-01-21
Loading full text...

Full text loading...

/deliver/fulltext/jgv/70/12/JV0700123177.html?itemId=/content/journal/jgv/10.1099/0022-1317-70-12-3177&mimeType=html&fmt=ahah

References

  1. Berman P. W., Gregory T., Crase D., Lasky L. A. 1985; Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D. Science 278:1490–1492
    [Google Scholar]
  2. Berman P. W., Vogt P. E., Gregory T., Lasky L. A., Kern E. R. 1988; Efficacy of recombinant glycoprotein D subunit vaccines on the development of primary, recurrent and latent genital infections with herpes simplex virus type 2 in guinea pigs. Journal of Infectious Diseases 157:897–902
    [Google Scholar]
  3. Bernstein D. I., Kappes J. C. 1988; Enhanced in vitro reactivation of latent herpes simplex virus from neural and peripheral tissues with hexamethylenebisacetamide. Archives of Virology 99:57–65
    [Google Scholar]
  4. Burke R. L., Pachl C., Quiroga M., Rosenberg S., Haigwood N., Nordfang O., Ezban M. 1986; The functional domains of coagulation factor VIII. Journal of Biological Chemistry 261:12574–12578
    [Google Scholar]
  5. Burke R. L., Van Nest G., Carlson J., Gervase B., Goldbeck C., Ng P., Sanchez-Pescador L., Stanberry L. R., Ott G. 1989; Development of a herpes simplex virus subunit vaccine. In Vaccines89 Chanock R. M., Lerner R. A. New York: Cold Spring Harbor Laboratory (in press);
    [Google Scholar]
  6. Chan W. L. 1983; Protective immunization of mice with specific HSV-1 glycoproteins. Immunology 49:343–352
    [Google Scholar]
  7. Dix R. D. 1987; Prospects for a vaccine against herpes simplex virus types 1 and 2. Progress in Medical Virology 34:89–128
    [Google Scholar]
  8. Dix R. D., Mills J. 1985; Acute and latent herpes simplex virus neurological disease in mice immunized with purified virus-specific glycoproteins gB and gD. Journal of Medical Virology 17:9–18
    [Google Scholar]
  9. Long D., Madara T. J., Ponce De Leon M., Cohen G. H., Montgomery P. C., Eisenberg R. J. 1984; Glycoprotein D protects mice against lethal challenge with herpes simplex virus types 1 and 2. Infection and Immunity 43:761–764
    [Google Scholar]
  10. Meignier B., Jourdier T. M., Norrild B., Pereira L., Roizman B. 1987; Immunization of experimental animals with reconstituted glycoprotein mixtures of herpes simplex virus 1 and 2: protection against challenge with virulent virus. Journal of Infectious Diseases 155:921–930
    [Google Scholar]
  11. Myers M. G., Bernstein D. I., Harrison C. J., Stanberry L. R. 1988; Herpes simplex virus glycoprotein treatment of recurrent genital herpes reduces cervicovaginal virus shedding in guineas pigs. Antiviral Research 10:83–88
    [Google Scholar]
  12. Pachl C., Burke R. L., Sanchez-Pescador L., Van Nest G., Masiars F., Dina D. 1987; Expression of cell-associated and secreted forms of herpes simplex virus type 1 glycoprotein B in mammalian cells. Journal of Virology 61:315–325
    [Google Scholar]
  13. Phillpots R. J., Welch M. G., Ridgeway P. H., Walkland A. C., Melling J. 1988; A test for the relative potency of herpes simplex virus vaccines based upon the female guinea-pig model of HSV-2 genital infection. Journal of Biological Standardization 16:109–118
    [Google Scholar]
  14. Prober G. G., Sullender W. M., Yasukawa L. L., Au D. S., Yeager A. S., Arvin A. M. 1988; Use of routine viral cultures at delivery to identify neonates exposed to herpes simplex virus. New England Journal of Medicine 316:240–244
    [Google Scholar]
  15. Roberts P. L., Duncan B. E., Raybould T. J. G., Watson D. H. 1985; Purification of herpes simplex virus glycoproteins B and C using monoclonal antibodies and their ability to protect mice against lethal challenge. Journal of General Virology 66:1073–1085
    [Google Scholar]
  16. Sanchez-Pescador L., Burke R. L., Ott G., Van Nest G. 1988; The effect of adjuvants on the efficacy of a recombinant HSV glycoprotein vaccine. Journal of Immunology 141:1720–1727
    [Google Scholar]
  17. Schrier R. D., Pizer L. I., Moorhead J. W. 1983; Type-specific delayed hypersensitivity and protection immunity induced by isolated herpes simplex virus glycoprotein. Journal of Immunology 130:1413–1418
    [Google Scholar]
  18. Stanberry L. R., Kern E. R., Richard J. T., Abbott T. M., Overall J. C. JR 1982; Genital herpes in guinea pigs: Pathogenesis of the primary infection and description of recurrent disease. Journal of Infectious Diseases 146:397–401
    [Google Scholar]
  19. Stanberry L. R., Kern E. R., Richard J. T., Overall J. C. JR 1985a; Recurrent genital herpes simplex virus infection in guinea pigs. Intervirology 24:226–231
    [Google Scholar]
  20. Stanberry L. R., Kit S., Myers M. G. 1985b; Thymidine kinase-deficient herpes simplex virus type 2 genital infection in guinea pigs. Journal of Virology 55:322–328
    [Google Scholar]
  21. Stanberry L. R., Bernstein D. I., Kit S., Myers M. G. 1986; Genital reinfection after recovery from initial genital infection with HSV-2 in guinea pigs. Journal of Infectious Diseases 153:1055–1061
    [Google Scholar]
  22. Stanberry L. R., Bernstein D. I., Burke R. L., Pachl C., Myers M. G. 1987; Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. Journal of Infectious Diseases 155:914–920
    [Google Scholar]
  23. Stanberry L. R., Burke R. L., Myers M. G. 1988; Herpes simplex virus glycoprotein treatment of recurrent genital herpes. Journal of Infectious Diseases 157:156–163
    [Google Scholar]
  24. Stephanopoulos D. E., Kappes J. C., Bernstein D. I. 1988; Enhanced in vitro reaction of herpes simplex virus type 2 from latently infected guinea-pig neural tissues by 5-azacytidine. Journal of General Virology 69:1079–1083
    [Google Scholar]
  25. Stuve L. L., Brown-Shimer S., Pachl C., Najarian R., Dina D., Burke R. L. 1987; Structure and expression of herpes simplex type 2 glycoprotein gB gene. Journal of Virology 61:326–335
    [Google Scholar]
  26. Thomson T. A., Hilfenhaus J., Moser H., Morahan P. S. 1983; Comparison of effects of adjuvants on efficacy of virion envelope herpes simplex virus vaccine against labial infection of BALB/c mice. Infection and Immunity 41:556–562
    [Google Scholar]
  27. Yeager A. S., Arvin A. M., Urbani L. J., Kemp J. A. 1980; Relationship of antibody to outcome in neonatal herpes simplex virus infections. Infection and Immunity 29:532–538
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-70-12-3177
Loading
/content/journal/jgv/10.1099/0022-1317-70-12-3177
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error